Participant flow

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · Source last updated 2024-01-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   SP-02L (darinaparsin for injection): Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days

   id

   FG000

   title

   SP-02L (Darinaparsin for Injection)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         65

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         56

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

67 patients were enrolled and 65 were treated.

recruitment Details

Patients were recruited in Japan, Korea, Taiwan and Hong Kong during the period from March 25, 2016 to September 17, 2019.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice